2 Winners for a Drug Development Future That Looks Nothing Like the Past
Things happen slowly and then all at once. At least that's how the saying goes. In hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. All of a sudden, it is responsible for a life-saving vaccine and spreading rapidly from the laboratory to clinical trials.
Genome sequencing and gene editing have been around for several years. However, new developments in each field are opening up doors that had been closed, and combining to usher in a new era for genomics. At the forefront are Pacific Biosciences of California (NASDAQ: PACB) and Beam Therapeutics (NASDAQ: BEAM). Each offers an upgrade from a technology that itself disrupted the status quo not long ago.
Image source: Getty Images.
Source Fool.com
